Overview
Caidya is a global contract research organization that provides outsourced clinical development services for biopharmaceuticals and medical devices. It covers pre-IND strategy, early- and late-stage trials, regulatory submissions, and post-marketing surveillance, offered through flexible models like standalone projects, full-service partnerships, and FSP arrangements. Its Clarity platform combines data from multiple systems for near real-time trial visibility and it integrates with Medidata Rave and Veeva to support trial delivery. The merged heritage of Clinipace and dMed Global, led by Dr. Lingshi Tan, gives a broad North America–Asia-Pacific footprint and deep expertise in oncology, rare diseases, cell and gene therapy, dermatology, and cardiology, with the goal of helping clients bring therapies to market efficiently and compliantly.
Work here?Claim your company
Simplify's take
What believers are saying
- Rubicon Founders’ $165 million investment in 2025 supports hiring, systems, and integration.
- August 2026 Caidya cited stronger demand in cell therapy, rare disease, and pharmacovigilance.
- Michael Clay’s February 2026 COO appointment strengthens delivery across over 50-country trials.
What critics are saying
- CRO consolidation pressure from IQVIA, Parexel, and Fortrea squeezes mid-market pricing in 2026.
- China execution exposes Caidya to NMPA shifts, data-transfer rules, and geopolitical scrutiny.
- If Simbec-Orion integration misses synergies, the combined platform loses credibility and contract wins.
What makes Caidya unique
- 2026 combination with Simbec-Orion adds early-phase pharmacology to Caidya’s global execution.
- Caidya spans Europe, Americas, Asia-Pacific, and China with bilingual regulatory teams.
- Its China bridging and APAC depth target sponsors needing localized execution across complex trials.
Help us improve and share your feedback! Did you find this helpful?